Ariana Boswell

All articles by Ariana Boswell

• Webinar explores clinical trial landscape for ATTR-CM

  In a recent webinar, Kristen Hsu of the Amyloidosis Research Consortium discussed the clinical trials currently being conducted for ATTR-CM.

• How to handle anxiety during the wait for ATTR-CM test results

  It’s normal to feel anxious while waiting for scan results.

• Webinar outlines current and emerging treatments for ATTR-CM

  In a recent webinar hosted by the Amyloidosis Research Consortium, Jan Griffin, MD discussed the expanding therapeutic landscape for ATTR-CM.

• Florbetaben (18F) receives orphan drug designation to diagnose ATTR

  The European Union has granted Orphan Drug Designation to the radioactive tracer florbetaben (18F) for the diagnosis of ATTR-CM.

• Review calls for more research on SGLT2 inhibitor use in ATTR-CM

  While SGLT2i may improve survival and cardiovascular outcomes in ATTR-CM, further research is needed to fully evaluate its clinical utility.

• Study finds new SPECT/CT approach may improve ATTR-CM diagnosis

  A recent study developed a simple mathematical tool that accurately detects cases of ATTR-CM based on SPECT/CT imaging.

• UK approves acoramidis to treat ATTR-CM

  Acoramidis, a transthyretin stabilizer, has been approved for adults living with ATTR-CM in the United Kingdom.

• Age, left atrium size associated with atrial fibrillation in ATTR-CM

  In a recent study, left atrial dilation and advanced age were identified as predictors of atrial fibrillation in patients with ATTR-CM.

• Nex-Z receives Regenerative Medicine Advanced Therapy designation for ATTR-CM

  Nex-z, a CRISPR/Cas9 therapy, was found to promote sustained and prolonged reduction of transthyretin levels in patients with ATTR-CM.

• Biomarkers of worsening ATTR-CM identified in patients on tafamidis

  NT-proBNP levels and oral diuretic use were associated with cardiac disease worsening in patients with ATTR-CM taking tafamidis.